TT-H3D17F5

TT-H3D17F5 is a monoclonal antibody being developed by THOR Biopharma, in collaboration with the Korea Advanced Institute of Science and Technology (KAIST), for the treatment of cancer cachexia. It specifically targets the GDNF family receptor alpha-like (GFRAL), a receptor primarily expressed in the hindbrain that mediates the metabolic effects of GDF15. By binding to GFRAL, the antibody inhibits the GDF15–GFRAL signaling axis, which is a key driver of the weight loss, muscle wasting, and anorexia associated with advanced malignancies such as lung, pancreatic, and colorectal cancers. The drug is currently in preclinical development as part of a dual-modality strategy that also includes an antisense oligonucleotide candidate targeting the same pathway.